Mallinckrodt PLC Company Profile (NYSE:MNK)

About Mallinckrodt PLC

Mallinckrodt PLC logoMallinckrodt public limited company (Mallinckrodt) is engaged in the specialty pharmaceuticals and nuclear imaging business. The Company develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products, and nuclear imaging agents. The Company's segments include Specialty Brands, Specialty Generics and Nuclear Imaging. Its Specialty Brands segment produces and markets branded pharmaceutical and biopharmaceutical products for autoimmune and rare diseases; immunotherapy and neonatal respiratory critical care therapies, and central nervous system drugs. Its Specialty Generics segment produces specialty generic pharmaceuticals and active pharmaceutical ingredients (API) consisting of biologics, medicinal opioids, synthetic controlled substances, acetaminophen and other active ingredients. Its Nuclear Imaging segment manufactures and markets radiopharmaceuticals (nuclear medicine).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NYSE
  • Symbol: MNK
  • CUSIP:
Key Metrics:
  • Previous Close: $74.92
  • 50 Day Moving Average: $72.16
  • 200 Day Moving Average: $64.45
  • Trailing P/E Ratio: 14.13
  • Foreward P/E Ratio: 8.11
  • P/E Growth: 0.21
  • Market Cap: $8.07B
  • Outstanding Shares: 107,713,000
  • Beta: 1.54
Additional Links:
Companies Related to Mallinckrodt PLC:

Analyst Ratings

Consensus Ratings for Mallinckrodt PLC (NYSE:MNK) (?)
Ratings Breakdown: 3 Hold Ratings, 14 Buy Ratings
Consensus Rating:Buy (Score: 2.82)
Consensus Price Target: $96.69 (29.05% upside)

Analysts' Ratings History for Mallinckrodt PLC (NYSE:MNK)
DateFirmActionRatingPrice TargetDetails
8/26/2016Goldman Sachs Group Inc.Reiterated RatingNeutral$83.00View Rating Details
8/25/2016BMO Capital MarketsReiterated RatingPositive -> Outperform$93.00View Rating Details
8/25/2016Barclays PLCReiterated RatingOverweight$88.00View Rating Details
8/24/2016Piper Jaffray Cos.Boost Price TargetOverweight$103.00 -> $112.00View Rating Details
8/13/2016MizuhoReiterated RatingBuy$91.00View Rating Details
8/12/2016Stifel NicolausInitiated CoverageBuy$95.00View Rating Details
8/4/2016Jefferies GroupReiterated RatingBuy$85.00 -> $95.00View Rating Details
8/3/2016JPMorgan Chase & Co.Set Price TargetHold$85.00View Rating Details
8/3/2016GuggenheimReiterated RatingBuy$98.00View Rating Details
8/3/2016Leerink SwannSet Price TargetBuy$84.00 -> $91.00View Rating Details
6/10/2016Wells Fargo & Co.Reiterated RatingBuyView Rating Details
5/4/2016Oppenheimer Holdings Inc.Reiterated RatingBuyView Rating Details
4/27/2016Morgan StanleyReiterated RatingBuyView Rating Details
3/16/2016Northland SecuritiesReiterated RatingBuy$95.00View Rating Details
2/2/2016NomuraReiterated RatingNeutral$100.00View Rating Details
11/24/2015Deutsche Bank AGLower Price TargetBuy$89.00 -> $87.00View Rating Details
10/7/2015Bank of America Corp.Lower Price TargetBuy$135.00 -> $131.00View Rating Details
1/30/2015CRT CapitalBoost Price TargetFairly Valued$84.00 -> $97.00View Rating Details
10/1/2014Buckingham ResearchBoost Price TargetBuy$107.00 -> $115.00View Rating Details
(Data available from 8/26/2014 forward)


Earnings History for Mallinckrodt PLC (NYSE:MNK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/2/2016Q316$2.00$2.20$920.35 million$970.60 millionViewListenView Earnings Details
5/3/2016Q216$1.72$2.01$878.70 million$918.00 millionViewListenView Earnings Details
2/2/2016Q116$1.77$2.00$888.33 million$915.00 millionViewListenView Earnings Details
11/23/2015Q415$1.77$1.84$869.41 million$882.40 millionViewListenView Earnings Details
8/4/2015Q315$1.82$2.05$983.81 million$965.10 millionViewListenView Earnings Details
5/5/2015Q215$1.48$1.72$860.89 million$909.90 millionViewListenView Earnings Details
2/3/2015Q115$1.55$1.84$880.12 million$866.00 millionViewListenView Earnings Details
11/19/2014Q414$1.41$1.68$759.04 million$789.00 millionViewListenView Earnings Details
8/7/2014Q314$0.87$1.20$278.80 million$653.10 millionViewListenView Earnings Details
5/8/2014Q214$0.78$0.95$566.50 million$557.80 millionViewListenView Earnings Details
2/6/2014Q1$0.66$0.88$539.24 million$540.20 millionViewListenView Earnings Details
11/7/2013$0.85$1.02$572.57 million$552.20 millionViewListenView Earnings Details
8/9/2013Q3 2013$0.78$0.49$557.22 million$570.00 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Mallinckrodt PLC (NYSE:MNK)
Current Year EPS Consensus Estimate: $8.76 EPS
Next Year EPS Consensus Estimate: $9.24 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 201610$1.64$1.87$1.77
Q2 20169$1.95$2.09$2.05
Q3 20163$1.98$2.14$2.04
Q4 20163$2.13$2.19$2.16
(Data provided by Zacks Investment Research)


Dividend History for Mallinckrodt PLC (NYSE:MNK)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Mallinckrodt PLC (NYSE:MNK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/10/2016Hugh M O'neillVPBuy1,653$60.99$100,816.47View SEC Filing  
5/10/2016Matthew K HarbaughCFOBuy500$59.37$29,685.00View SEC Filing  
5/6/2016Mark TrudeauCEOBuy1,000$56.02$56,020.00View SEC Filing  
5/6/2016Steven J RomanoVPBuy900$56.00$50,400.00View SEC Filing  
3/4/2016Coleman N Lannum IIIVPBuy2,600$62.63$162,838.00View SEC Filing  
2/26/2016Meredith B FischerVPBuy1,400$69.80$97,720.00View SEC Filing  
2/12/2016Coleman N Lannum IIIVPBuy600$59.66$35,796.00View SEC Filing  
2/10/2016Coleman N Lannum IIIVPBuy1,300$62.58$81,354.00View SEC Filing  
2/9/2016Matthew K. HarbaughCFOBuy1,300$63.00$81,900.00View SEC Filing  
2/8/2016Coleman N. Lannum IIIVPBuy800$66.37$53,096.00View SEC Filing  
12/22/2015Coleman N Lannum IIISVPBuy500$72.50$36,250.00View SEC Filing  
12/11/2015Terrance L CarlsonGeneral CounselBuy1,000$69.10$69,100.00View SEC Filing  
12/2/2015Gary M. PhillipsVPBuy1,000$72.17$72,170.00View SEC Filing  
11/30/2015Mark TrudeauCEOBuy1,350$65.89$88,951.50View SEC Filing  
11/27/2015Coleman N Lannum IIISVPBuy1,200$66.86$80,232.00View SEC Filing  
11/27/2015Meredith B FischerVPBuy2,200$66.93$147,246.00View SEC Filing  
11/27/2015Terrance L CarlsonGeneral CounselBuy1,000$66.54$66,540.00View SEC Filing  
8/25/2015Hugh M O'neillSVPBuy1,197$83.52$99,973.44View SEC Filing  
8/25/2015Mark TrudeauCEOBuy1,000$83.08$83,080.00View SEC Filing  
8/21/2015Coleman N Lannum IIISVPBuy2,375$88.52$210,235.00View SEC Filing  
8/21/2015Mark TrudeauCEOBuy2,000$88.45$176,900.00View SEC Filing  
6/4/2015Coleman N Lannum IIIVPBuy1,300$126.41$164,333.00View SEC Filing  
6/2/2015Matthew K HarbaughCFOSell22,106$128.64$2,843,715.84View SEC Filing  
5/18/2015Mario D SaltarelliVPSell4,580$127.44$583,675.20View SEC Filing  
5/13/2015Don M BaileyDirectorSell51,417$122.45$6,296,011.65View SEC Filing  
5/11/2015Sandra L HattenVPSell2,024$122.29$247,514.96View SEC Filing  
4/13/2015Don M BaileyDirectorSell40,000$127.61$5,104,400.00View SEC Filing  
3/13/2015Don M BaileyDirectorSell40,000$123.40$4,936,000.00View SEC Filing  
2/13/2015Don M BaileyDirectorSell33,891$114.63$3,884,925.33View SEC Filing  
2/2/2015Mark TrudeauCEOSell11,925$105.94$1,263,334.50View SEC Filing  
1/9/2015Mark TrudeauCEOSell15,720$102.00$1,603,440.00View SEC Filing  
12/22/2014Peter G EdwardsVPSell1,265$99.69$126,107.85View SEC Filing  
12/18/2014Mark TrudeauCEOSell13,831$93.59$1,294,443.29View SEC Filing  
9/10/2014Raymond J FureyVPSell5,441$85.90$467,381.90View SEC Filing  
9/8/2014Don M BaileyDirectorSell221,177$85.23$18,850,915.71View SEC Filing  
9/5/2014Raymond J FureyVPSell15,000$85.47$1,282,050.00View SEC Filing  
9/5/2014Virgil D ThompsonDirectorSell25,000$83.76$2,094,000.00View SEC Filing  
9/2/2014Raymond J FureyVPSell10,303$81.61$840,827.83View SEC Filing  
8/29/2014Raymond J FureyVPSell4,840$80.90$391,556.00View SEC Filing  
8/19/2014Joseph A ZaccagninoDirectorBuy3,000$71.06$213,180.00View SEC Filing  
8/13/2014Paulson & Co IncMajor ShareholderBuy132,100$69.80$9,220,580.00View SEC Filing  
8/12/2014J Martin CarrollDirectorBuy2,000$69.24$138,480.00View SEC Filing  
8/12/2014Paulson & Co IncMajor ShareholderBuy467,900$68.78$32,182,162.00View SEC Filing  
8/11/2014Paulson & Co IncMajor ShareholderBuy207,900$69.70$14,490,630.00View SEC Filing  
8/7/2014Paulson & Co IncMajor ShareholderBuy700,200$70.15$49,119,030.00View SEC Filing  
8/1/2014Paulson & Co IncMajor ShareholderBuy275,000$69.60$19,140,000.00View SEC Filing  
6/11/2014Melvin D BoothDirectorBuy4,000$76.05$304,200.00View SEC Filing  
5/9/2014Paulson & Co Incmajor shareholderBuy786,207$73.63$57,888,421.41View SEC Filing  
2/3/2014Mark TrudeauCEOSell14,890$56.12$835,626.80View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Mallinckrodt PLC (NYSE:MNK)
News IconMallinckrodt PLC (NYSE:MNK), UnitedHealth Group Inc (NYSE:UNH) - NYSE Journal (press release) (NYSE:MNK) - August 26 at 5:59 PM logoShort Interest Drops 21.8% For MNK (NYSE:MNK) - August 25 at 6:10 PM logoMallinckrodt's Top Drug Could Go the Way of EpiPen (NYSE:MNK) - August 25 at 11:20 AM logoMallinckrodt Could Be Next in Spotlight Thanks to EpiPen Scrutiny (NYSE:MNK) - August 25 at 11:20 AM logoPiper Jaffray Stays Bullish on Mallinckrodt (MNK), Lifts PT to $112 (NYSE:MNK) - August 24 at 9:20 AM logoMALLINCKRODT PLC Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial (NYSE:MNK) - August 24 at 9:20 AM logoMallinckrodt sells nuclear imaging business for $690 million (NYSE:MNK) - August 24 at 9:20 AM logoMallinckrodt Enters Agreement To Sell Its Nuclear Imaging Business To IBA Molecular For Approximately $690 Million (NYSE:MNK) - August 24 at 9:20 AM logoMallinckrodt to sell nuclear imaging business for $690 million (NYSE:MNK) - August 24 at 9:20 AM logo[$$] Mallinckrodt to Sell Nuclear-Imaging Operations (NYSE:MNK) - August 24 at 9:20 AM logoExtracorporeal Photopheresis (ECP), Including Mallinckrodt's THERAKOS® ECP Immunomodulation, Receives … (NYSE:MNK) - August 23 at 10:39 AM logoMallinckrodt Says Switzerland Okays ECP For Reimbursement (NYSE:MNK) - August 23 at 10:39 AM logoExtracorporeal Photopheresis (ECP), Including Mallinckrodt's THERAKOS® ECP Immunomodulation, Receives Approval for Reimbursement by Swiss Federal Department of Home Affairs (NYSE:MNK) - August 23 at 10:39 AM logoMallinckrodt To Present At Morgan Stanley Global Healthcare Conference (NYSE:MNK) - August 22 at 10:48 AM logoAnalysts See Mallinckrodt plc (NYSE:MNK) Reporting EPS Of $2.32 (NYSE:MNK) - August 21 at 5:36 PM logoMallinckrodt To Present At Wells Fargo Securities Healthcare Conference (NYSE:MNK) - August 19 at 9:16 AM logoBehind Horizon’s Price-to-Sales Valuation (NYSE:MNK) - August 18 at 6:22 PM logoMallinckrodt Locates Growing Specialty Brands Businesses In Bedminster, N.J.; Continues Significant St. Louis Reinvestment (NYSE:MNK) - August 18 at 9:18 AM
News IconBlog Coverage Mallinckrodt Acquires Privately Held Regenerative Skin Technology Firm (NYSE:MNK) - August 12 at 9:28 AM logoMallinckrodt buys regenerative med firm specializing in skin substitutes (NYSE:MNK) - August 11 at 9:24 AM
News IconCovidien spinout Mallinckrodt to acquire Stratatech (NYSE:MNK) - August 11 at 9:24 AM logoMallinckrodt Stock Sees Short Interest Move 15.6% Lower (NYSE:MNK) - August 10 at 6:38 PM logoMallinckrodt (MNK) to Acquire Stratatech (NYSE:MNK) - August 10 at 6:38 PM logoMallinckrodt plc (NYSE:MNK) Boasts Rating Of 1.04 (NYSE:MNK) - August 10 at 6:38 PM logo5:47 pm Mallinckrodt to acquire Stratatech Corporation, a regenerative medicine company focused on therapeutic human skin substitute products; Financial terms were not disclosed (NYSE:MNK) - August 10 at 6:38 PM logoMallinckrodt To Acquire Stratatech Corporation, A Regenerative Medicine Company Focused On Proprietary Therapeutic Human Skin Substitute Products (NYSE:MNK) - August 10 at 6:38 PM logoMallinckrodt Takes Over #5 Spot From Lam Research (NYSE:MNK) - August 10 at 9:17 AM logoLarge Inflow of Money Detected in Mallinckrodt plc (NYSE:MNK) - August 10 at 9:17 AM logoMALLINCKRODT PLC Financials (NYSE:MNK) - August 9 at 6:29 PM logoMallinckrodt plc (MNK) Shares are Up 18.79% - Trade Calls (NYSE:MNK) - August 9 at 9:23 AM logoThe death of short sellers? (NYSE:MNK) - August 8 at 6:27 PM logoMallinckrodt plc (MNK) is Trading Higher on Unusual Volume for August 03 - (NYSE:MNK) - August 5 at 6:23 PM logoFalls Continue in Specialty Generics and Nuclear Imaging (NYSE:MNK) - August 5 at 9:19 AM logoSizzling S&P sectors for summer (NYSE:MNK) - August 4 at 9:24 AM logoHow Did Mallinckrodt’s Specialty Brands Perform in Fiscal 3Q16? (NYSE:MNK) - August 4 at 9:24 AM logoMallinckrodt plc (NYSE:MNK): The Buzzing Stock - Stocks Daily (NYSE:MNK) - August 3 at 6:35 PM logoAnalyst's Checklist Stocks: Mallinckrodt plc (NYSE:MNK) , Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - Street Updates (NYSE:MNK) - August 3 at 6:35 PM
News IconFiat Chrysler Automobiles NV (NYSE:FCAU) & Mallinckrodt PLC (NYSE:MNK) Notable Runners - Money News (press release) (NYSE:MNK) - August 3 at 6:35 PM logoMallinckrodt Plc: Strong price momentum but will it sustain? (NYSE:MNK) - August 3 at 6:35 PM logoMallinckrodt PLC (MNK) Punishes Shorts on Post-Earnings Pop (NYSE:MNK) - August 3 at 9:33 AM logoMallinckrodt (MNK) PT Raised to $95 at Jefferies (NYSE:MNK) - August 3 at 9:33 AM logoEarnings Reaction History: Mallinckrodt plc, 33.3% Follow-Through ... - Nasdaq (NYSE:MNK) - August 2 at 6:32 PM logoMallinckrodt PLC (MNK) Punishes Shorts on Post-Earnings Pop - Schaeffers Research (blog) (NYSE:MNK) - August 2 at 6:32 PM logoMallinckrodt (MNK) Tops Q3 Earnings on Solid Sales Growth (NYSE:MNK) - August 2 at 6:32 PM logoMallinckrodt leads S&P after second-quarter results beat the Street (NYSE:MNK) - August 2 at 6:32 PM logoMARKET SNAPSHOT: Dow Industrials On Pace For Seven-session Losing Streak (NYSE:MNK) - August 2 at 11:03 AM logoDow industrials on pace for seven-session losing streak (NYSE:MNK) - August 2 at 11:03 AM logoMallinckrodt plc: Mallinckrodt plc Reports Fiscal 2016 Third Quarter Results and Provides Guidance for Calendar Year 2016 (NYSE:MNK) - August 2 at 11:03 AM logoNot Dead Yet: Shire, Mallinckrodt Beat Estimates, Kicking Off Specialty Rx Earnings Season (NYSE:MNK) - August 2 at 11:03 AM logoMallinckrodt (MNK) Stock Spikes on Q3 Beat, Forecast (NYSE:MNK) - August 2 at 11:03 AM


Mallinckrodt PLC (NYSE:MNK) Chart for Friday, August, 26, 2016

Last Updated on 8/26/2016 by Staff